The cyclin-dependent kinase inhibitor flavopiridol potentiates doxorubicin efficacy in advanced sarcomas: preclinical investigations and results of a phase I dose escalation clinical trial

BACKGROUND: Dysregulated cyclin-dependent kinases (CDKs) are important to the growth of some sarcomas. Flavopiridol is a pan-CDK inhibitor that has been shown to potentiate chemotherapy. As such, we explored the potentiation of doxorubicin by flavopiridol in sarcoma, in vitro and in vivo, and perfor...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Luke, Jason J., D’Adamo, David R., Dickson, Mark A., Keohan, Mary Louise, Carvajal, Richard D., Maki, Robert G., de Stanchina, Elisa, Musi, Elgilda, Singer, Samuel, Schwartz, Gary K.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2012
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3343204/
https://ncbi.nlm.nih.gov/pubmed/22374332
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-11-3203
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi